The present application relates to a use for cartilage regeneration and/or use for osteoarthritis treatment of a mesenchymal stem cell expressing TSG-6 protein. The present application provides a composition for cartilage regeneration and a pharmaceutical composition for osteoarthritis treatment, comprising a mesenchymal stem cell expressing TSG-6 protein as an active ingredient. The composition for cartilage regeneration and/or the pharmaceutical composition for osteoarthritis treatment provided by the present application can increase collagen expression of cartilage cells, reduce inflammation, and restore the cartilage structure.

Disclosed herein is a technology for healing bone defects using bioactive silicate glass (BSG) and a 3D osteomimetic composite porous scaffold containing microspheres comprised of poly(lactide-co-glycolide) (PLGA).

Synthetic polymers, e.g., synthetic heparin mimetics, are provided, including hydrogel compositions incorporating the synthetic polymers. Methods of making and using the synthetic polymers are also provided.

The present disclosure relates to compositions and methods for modulating wound healing and regeneration. More particularly, the present disclosure relates to immunomodulatory agents that promote wound healing and tissue regeneration, and that may be optionally used in combination with synthetic or bio-material scaffolds.

The present disclosure provides fasciculated nerve grafts of customizable lengths and diameters, and methods of preparing the same. The grafts are made by digesting native extracellular matrix (ECM) around the nerve fascicles of a nerve tissue, and the epineurial sheath. One or more of the individual fascicles may then be entubulated in an entubulation material, embedded in or coated with a coating material, or both, to form a fasciculated nerve graft. The fasciculated nerve grafts are customizable and designed to bridge nerve gaps; the modularity of the fasciculated nerve graft allows for restoring continuity to nerve defects of virtually any length and allows for matching the diameter of the patient's recipient nerve.

Methods and compositions for reducing the activity or number of memory Th17 cells in ocular tissue, and for treatment and/or prevention of ocular immunoinflammatory diseases are described.

Nanofiber structures are provided as well as methods of use thereof and methods of making.

A disposable device for treating a condition of a ureter or kidney having a cylindrical body about 1-2 mm in diameter by about 5 to 10 mm in length and having a top and bottom end. The body is made of absorbent material that expands upon contact with pharmaceutical agent and bodily fluids and includes a string connected to the bottom end of the body for removing the device. The device can be used to treat a condition of the ureter or kidney by inserting into the ureter or kidney, delivering a pharmaceutical agent, and removing the device after it has been impregnated with fluid. The device can be included in a kit with an insertion device and/or appropriate pharmaceutical agents.

One aspect of the invention provides a method of treating a chronic wound including administering to the wound at least one agent from a delivery system wherein the agent induces sequential conversion of a first population of wound macrophages in the wound to M2A macrophages and a second population of wound macrophages to M2C macrophages. The sequential conversion of the wound macrophages promotes tissue remodeling.

The present invention provides compositions for treating soft tissue injuries comprising a collagen matrix and mesenchymal stem cells adhered to the collagen matrix. Methods of making and using compositions comprising a collagen matrix and mesenchymal stem cells adhered to the collagen matrix are also provided.